Myasthenia Gravis clinical trials at UC Irvine
1 research study open to eligible people
open to eligible people ages 18 years and up
The purpose of the current study is to assess safety/tolerability and key pharmacodynamic (PD) effects that are considered to be associated with clinical benefit (reduction of total IgG and anti-AChR-IgG) in Myasthenia Gravis patients following treatment with RVT-1401 (also known as IMVT-1401) compared to placebo.
Orange, California and other locations